Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 16/20 | 0.57 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.57 |
| ▸ | MASP2 | O00187 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 2/20 | 0.32 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18697145 | 0.92 | KLKB1 (0.57) | KLKB1MAP4K1MASP2F7F3 | |
| SCHEMBL20616378 | 0.79 | KLKB1 (0.55) | KLKB1MAP4K1KLK1 | |
| SCHEMBL19354570 | 0.76 | KLKB1 (0.45) | KLKB1MAP4K1KLK1 | |
| SCHEMBL18458794 | 0.75 | KLKB1 (0.55) | KLKB1MAP4K1KLK1 | |
| SCHEMBL18697172 | 0.74 | KLKB1 (0.60) | KLKB1MAP4K1KLK1 | |
| SCHEMBL16880670 | 0.73 | KLKB1 (1.00) | KLKB1MAP4K1 | |
| SCHEMBL21064331 | 0.73 | KLKB1 (0.45) | KLKB1MAP4K1 | |
| SCHEMBL18697232 | 0.72 | KLKB1 (0.55) | KLKB1MAP4K1 | |
| SCHEMBL18458339 | 0.72 | KLKB1 (0.45) | KLKB1MAP4K1 | |
| SCHEMBL19354844 | 0.72 | KLKB1 (0.57) | KLKB1MAP4K1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266515-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-23 | — | — | US | disclosed |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885MASP2 37/4885 |
| US-10266515-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885MASP2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.